Wissenschaftliche Arbeiten

Doç. Dr. Özlem Nuray Sever

81 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study

    Clinical Medicine Insights Oncology, 2026

    DOI 10.1177/11795549261445290 PMID 42131419 Frei zugänglicher VolltextQuelle: OpenAlex

  2. Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors

    JCO Global Oncology, 2026

    DOI 10.1200/go-25-00234 PMID 41855443 Frei zugänglicher VolltextQuelle: OpenAlex

  3. Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study

    Cancers, 2026

    DOI 10.3390/cancers18132127 PMID 42449669 Frei zugänglicher VolltextQuelle: OpenAlex

  4. Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16664-1 Frei zugänglicher VolltextQuelle: OpenAlex

  5. Prognostic role of smoking in metastatic renal cell carcinoma in real-world data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-35435-3 PMID 41548007 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  6. Prognostic Value of the Cancer Inflammation Prognostic Index (CIPI) in De Novo Metastatic Colon Cancer: A Multicenter Retrospective Cohort Study

    Cancer Control, 2026

    DOI 10.1177/10732748261432273 PMID 41779425 Frei zugänglicher VolltextQuelle: ORCID

  7. Optimizing Antiemetic Strategies Across Phases of Chemotherapy-Induced Nausea and Vomiting: Real-World Evidence in Breast Cancer

    Current Oncology, 2026

    DOI 10.3390/curroncol33020078 PMID 41744842 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  8. Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14197103 PMID 41096183 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  9. The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-14252-3 PMID 40329228 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  10. Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

    癌症：英文版, 2025

    DOI 10.1002/cac2.70003 PMID 39927571 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  11. The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer Consortium

    The Oncologist, 2025

    DOI 10.1093/oncolo/oyaf186 PMID 40577354 Frei zugänglicher VolltextQuelle: OpenAlex

  12. Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

    Immunotherapy, 2025

    DOI 10.1080/1750743x.2025.2527019 PMID 40611593 Frei zugänglicher VolltextQuelle: OpenAlex

  13. Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study

    Medicina, 2025

    DOI 10.3390/medicina61010154 PMID 39859134 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  14. Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    Clinical and Translational Oncology, 2025

    DOI 10.1007/s12094-024-03813-w PMID 39812937 6 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  15. Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-14654-3 PMID 40713516 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  16. Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium

    Therapeutic Advances in Medical Oncology, 2025

    DOI 10.1177/17588359251331540 PMID 40297625 Frei zugänglicher VolltextQuelle: ORCID

  17. Efficacy of Palbociclib and Ribociclib in Second-line Treatment of Metastatic Hormone Receptor-positive Breast Cancer: A Single-center Experience

    Journal of Oncological Science, 2025

    DOI 10.37047/jos.galenos.2025.2025-4-2 Frei zugänglicher VolltextQuelle: ORCID

  18. Relationship of Tumor Localization and Lipid Parameters with Survival in Patients with Colorectal Cancer

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14041302 PMID 40004832 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  19. Long-term Follow-up Results of Our Patients Diagnosed with Ductal Carcinoma In Situ: Usefulness of the Van Nuys Prognostic Index

    Journal of Oncological Sciences, 2025

    DOI 10.37047/jos.galenos.2025.2025-3-13 Frei zugänglicher VolltextQuelle: OpenAlex

  20. The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-63096-7 PMID 38802494 21 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  21. Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis

    Medicina, 2024

    DOI 10.3390/medicina60081374 PMID 39202654 10 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  22. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status

    Chemotherapy, 2024

    DOI 10.1159/000537874 PMID 38368871 5 Zitationen (Europe PMC) Quelle: OpenAlex

  23. A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

    Cancers, 2024

    DOI 10.3390/cancers16142512 PMID 39061152 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  24. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

    Journal of Clinical Medicine, 2024

    DOI 10.3390/jcm13206263 PMID 39458213 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  25. Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?

    Medicina, 2024

    DOI 10.3390/medicina60081372 PMID 39202652 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  26. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy

    Cureus, 2024

    DOI 10.7759/cureus.63362 PMID 39070363 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  27. Prognostic scores in pulmonary large cell neuroendocrine carcinoma: A retrospective cohort study

    Heliyon, 2024

    DOI 10.1016/j.heliyon.2024.e25029 PMID 38317875 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  28. Efficacy and Safety of Ixabepilone in Metastatic Breast Cancer After Multiple Treatments: Analysis Based on Real-World Data

    Journal of Oncological Sciences, 2024

    DOI 10.37047/jos.2024-102164 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  29. The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma

    Journal of Immunotherapy, 2024

    DOI 10.1097/cji.0000000000000508 PMID 38333962 7 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  30. Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102282 PMID 39709686 2 Zitationen (Europe PMC) Quelle: OpenAlex

  31. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

    2024

    DOI 10.20944/preprints202409.0812.v1 Frei zugänglicher VolltextQuelle: ORCID

  32. The Predictive Value of Urinary HMGB1 Level in the Diagnosis and Prognosis of Renal Cell Carcinoma

    Eurasian Journal of Medical Advances, 2024

    DOI 10.14744/ejma.2024.93063 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  33. The association of hemoglobin/red blood distribution width with overall survival: a retrospective analysis of melanoma

    Esperienze Dermatologiche, 2023

    DOI 10.23736/s1128-9155.23.00556-3 1 Zitation (OpenAlex) Quelle: OpenAlex

  34. 177Lu-PSMA-617 RLT in mCRPC: A single center experience, the earlier could be the better

    Revista Espanola de Medicina Nuclear E Imagen Molecular, 2023

    DOI 10.1016/j.remn.2021.11.004 Quelle: ORCID

  35. Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium

    Urologia Internationalis, 2023

    DOI 10.1159/000528994 PMID 36996793 3 Zitationen (Europe PMC) Quelle: ORCID

  36. Onkolojide Güncel Tedavi Yaklaşımları 1

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1606 Quelle: OpenAlex

  37. Comparison of 68Ga-FAPI PET/CT and 18FDG PET/CT Modalities in Gastrointestinal System Malignancies with Peritoneal Involvement

    Molecular Imaging and Biology, 2022

    DOI 10.1007/s11307-022-01729-x PMID 35411447 35 Zitationen (Europe PMC) Quelle: OpenAlex

  38. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

    Clinical Genitourinary Cancer, 2022

    DOI 10.1016/j.clgc.2022.07.006 PMID 35970759 6 Zitationen (Europe PMC) Quelle: OpenAlex

  39. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04055-5 PMID 35616728 22 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  40. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors

    Scientific Reports, 2022

    DOI 10.1038/s41598-022-20056-3 PMID 36192500 15 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  41. Gastrointestinal Sistem Tümörleri-2

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1212 Frei zugänglicher VolltextQuelle: OpenAlex

  42. Role of serum cathelicidin in diagnosis of patient with prostatitis and prostate carcinoma

    African Journal of Urology, 2022

    DOI 10.1186/s12301-022-00330-6 Frei zugänglicher VolltextQuelle: ORCID

  43. 177Lu-PSMA-617 RLT in mCRPC: A single center experience, the earlier could be the better

    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2022

    DOI 10.1016/j.remnie.2021.12.005 PMID 35193812 4 Zitationen (OpenAlex) Quelle: OpenAlex

  44. Our Experience with Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer: Retrospective Real-Life Data

    Journal of Oncological Sciences, 2022

    DOI 10.37047/jos.2021-85879 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  45. The role of exosomal survivin in the diagnosis of breast cancer

    International Journal of Clinical Biochemistry and Research, 2022

    DOI 10.18231/j.ijcbr.2022.049 3 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  46. CLINICAL FACTORS PREDICTING RESPONSE TO REGORAFENIB IN METASTATIC COLORECTAL CANCER

    Euroasia Journal of Mathematics Engineering Natural and Medical Sciences, 2022

    DOI 10.38065/euroasiaorg.924 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  47. Survival Analysis of Our Patients Diagnosed with Testicular Cancer

    Eurasian Journal of Medical Investigation, 2022

    DOI 10.14744/ejmi.2022.66533 Quelle: OpenAlex

  48. Tumor Microenvironment and Mechanisms of Cancer Metastasis: An Overlooked Fact: Cell Fusion

    Journal of Oncological Sciences, 2022

    DOI 10.37047/jos.2022-89872 Frei zugänglicher VolltextQuelle: OpenAlex

  49. Mide ve Kolorektal Kanser ile Serum Gama Glutamil Transferaz Düzeyleri Arasındaki İlişkinin İncelenmesi

    Acta Medica Nicomedia, 2022

    DOI 10.53446/actamednicomedia.1110063 Frei zugänglicher VolltextQuelle: OpenAlex

  50. Efficacy and Tolerability of Current Treatments for Hormone-Refractory Prostate Cancer Patients with Visceral Metastases

    Future Oncology, 2021

    DOI 10.2217/fon-2020-1032 PMID 33631986 Quelle: OpenAlex